Home CompaniesSectorsHealth CareBiotechnologyParabilis Medicines Is a $3.56B Biotech With $2M of Revenue: Reading the Risk First

Parabilis Medicines Is a $3.56B Biotech With $2M of Revenue: Reading the Risk First

by Chaudhry Kramat Ali
0 comments
Parabilis Medicines, Inc. stock analysis

Key Takeaways

  • Quality: an operating margin of -8509.8% on about $2M of revenue shows deep losses, partly cushioned by a current ratio of 12.88 and debt-to-equity of just 0.04.
  • Growth: revenue and earnings growth are N/A, and an EV/Revenue of 1207.46 means the valuation rests on the pipeline rather than current sales.
  • Opportunity: with no P/E or free cash flow yield, the model issues no signal; the price sits in the lower end of its $22.75 to $41.73 two-year range.

PBLS

Parabilis Medicines, Inc.

$28.40

Market Cap
$3.56B

P/E Ratio
N/A

2-Year Position

$22.75$41.73

Signal
N/A

This Parabilis Medicines, Inc. stock analysis begins with the risk profile, because the numbers call for it. The company is a pre-profit biotechnology name with a market capitalization of $3.56B, trailing-twelve-month revenue of about $2M and earnings per share of -$9.51. The shares traded at $28.40 on November 17, 2026. The scoring model gives a Quality score of 34/100 but cannot score Growth or Opportunity, so no Buy, Hold or Sell signal is issued.

What Is Happening With the Stock Price

At $28.40, the stock sits in the lower end of its two-year range, which runs from a low of $22.75 to a high of $41.73. The price is closer to the bottom of that band than the top, but the range covers only two years and carries no dates, so it says little about why the shares moved. For a clinical-stage-style business with negligible revenue, the price is driven by expectations about the pipeline rather than by current earnings, which makes outcomes highly uncertain in both directions.

Quality: Is This a Financially Sound Business?

Profitability metrics show a company that is early in its commercial life. Operating margin is -8509.8%, which on $2M of revenue implies an operating loss on the order of $190M. Gross margin is reported as 0.0%, which is unusual for a company that books any revenue at all; it may reflect how a small collaboration or licensing revenue line is classified rather than a true cost structure, but the data does not say. Net profit margin, return on equity, return on assets and free cash flow are all N/A, so earnings and cash-flow quality cannot be judged. The balance sheet is the bright spot: debt-to-equity is 0.04, the current ratio is 12.88 and the quick ratio is 12.78. That points to ample liquidity and minimal debt, which matters for a company that is burning cash. Still, the heavy losses mean dilution through future share issuance is a real possibility. This Parabilis Medicines stock analysis cannot confirm how long the current cash lasts, since free cash flow is not available.

Growth: Does This Company Have Real Upside?

Revenue growth over the trailing twelve months and the five-year CAGR are both N/A, as is earnings growth, so the model has no growth evidence to work with. EV/Revenue is 1207.46, an extreme figure that simply reflects a multi-billion-dollar enterprise value set against about $2M of sales. It signals that investors are valuing the pipeline, not the revenue. EV/EBITDA is -14.37, negative because EBITDA is negative. Any upside case depends on clinical or commercial outcomes that these metrics cannot capture.

Opportunity: Is Now a Good Time to Enter?

The Opportunity score is N/A. There is no P/E ratio because earnings are negative, and the free cash flow yield is N/A. The one usable valuation anchor is price-to-book at 3.50, which is modest next to the revenue multiple but does not by itself indicate cheapness for a company with no profits. The share price sits in the lower part of its two-year range, which some investors may view as a more favorable starting point than the highs, though a lower price does not reduce the underlying uncertainty. There is no dividend.

Parabilis Medicines, Inc. Stock Analysis: The Bottom Line

The case for the shares rests on a strong liquidity position, almost no debt and a market that evidently values the pipeline. The case against is stark: an operating margin of -8509.8%, no earnings or free cash flow to measure, and a valuation that depends entirely on future results. Because Growth and Opportunity lack adequate evidence, the StreetBriefs model does not issue a signal for this stock, and the N/A badge reflects that. The Quality score of 34/100 is a research starting point, not a personalized recommendation to transact. This Parabilis Medicines, Inc. stock analysis is based on Yahoo Finance data as of November 17, 2026, which may be delayed or contain errors.

Financial Metrics Summary

Metric Value
Price & Valuation
Current Price $28.40
2-Year Low $22.75
2-Year High $41.73
Market Cap $3.56B
EV / Revenue 1207.46
Our Scores
Quality Score 34 / 100
Profitability
Earnings Per Share -$9.51
Gross Margin 0.0%
Operating Margin -8509.8%
Balance Sheet
Debt-to-Equity 0.04
Current Ratio 12.88
Quick Ratio 12.78
Income & Dividends
Dividend Yield 0.0%

Data as of November 17, 2026

Our Three-Pillar Assessment

Quality

34/100

Growth

N/A

Opportunity

N/A

N/A

OVERALL SIGNAL
Buy / Hold / Sell reflects StreetBriefs’ quantitative scoring model (Quality, Growth, Opportunity) – a data-driven signal for further research, not a personalized recommendation to transact.

Quality measures business fundamentals: profitability, cash flow discipline, and balance sheet strength.

Growth captures revenue momentum, gross margin scalability, and the Rule of 40 efficiency test.

Opportunity signals entry timing: current valuation versus history and price position in the 2-year range.

Current price: $28.40 trading 32% below its 2-year high of $41.73.

Keep researching PBLS

Follow PBLS’s scores in Qubits Finance

The Quality, Growth and Opportunity scores above come from the same model that powers the Qubits Finance screener. Compare PBLS with its peers, keep it on a watchlist, and see when its scores change. There, the model’s Buy, Hold and Sell signals read Positive, Neutral and Caution.

See PBLS in the screener →What Qubits Finance offers

The screener is on the free plan; accounts are approved by a person during the private beta. Research tools and information only: Qubits Finance does not place trades or make personal recommendations. Want a stock we have not covered? Request an analysis.

This analysis is done using financial data from Yahoo Finance.

Disclaimer: This article is written for informational purposes only and does not constitute investment advice. The analysis is based on publicly available financial data and interpretation of company fundamentals.
Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions.

You may also like

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted